Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Curr Eye Res ; 46(3): 380-386, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-32706598

RESUMO

AIM: The aim of this study was to compare the ocular and systemic absorption of brimonidine (BMD) and brinzolamide (BZM) in rabbits after the topical administration of a fixed-combination ophthalmic suspension of 0.1% BMD tartrate and 1% BZM (FCBB) with that after the administration of the respective single-drug formulations. MATERIALS AND METHODS: Ocular and systemic drug absorption was estimated by determining BMD and BZM concentrations in the aqueous humor, retina/choroid, vitreous body, and blood/plasma by liquid chromatography/tandem mass spectrometry after the administration of FCBB, 0.1% BMD tartrate ophthalmic solution (0.1% BMD), or 1% BZM ophthalmic suspension (1% BZM) to rabbits. RESULTS: In concomitant administration, instilling 0.1% BMD and 1% BZM successively without interval lowered aqueous humor concentrations of both drugs compared to those observed with a 5-min interval. After FCBB administration, BMD and BZM concentrations in the aqueous humor were comparable with those observed after the administration of 0.1% BMD and 1% BZM, whereas BMD concentrations in posterior ocular tissues were equal to or higher than those observed after 0.1% BMD. Plasma BMD concentrations following the administration of FCBB were 0.8-fold lower than those after 0.1% BMD; no remarkable differences were observed in blood BZM concentrations for both formulations. CONCLUSIONS: FCBB achieved drug distribution in the aqueous humor and systemic exposure that were comparable to those for the single-drug formulations. The viscosity of FCBB may increase BMD distribution in the retina/choroid. The administration interval affects ocular drug absorption with the concomitant administration of 0.1% BMD and 1% BZM, which can be overcome by using the fixed-combination of both drugs.


Assuntos
Humor Aquoso/metabolismo , Tartarato de Brimonidina/farmacocinética , Glaucoma/tratamento farmacológico , Sulfonamidas/farmacocinética , Tiazinas/farmacocinética , Corpo Vítreo/metabolismo , Administração Tópica , Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Agonistas de Receptores Adrenérgicos alfa 2/farmacocinética , Animais , Humor Aquoso/efeitos dos fármacos , Tartarato de Brimonidina/administração & dosagem , Inibidores da Anidrase Carbônica/administração & dosagem , Inibidores da Anidrase Carbônica/farmacocinética , Cromatografia Líquida de Alta Pressão , Modelos Animais de Doenças , Composição de Medicamentos , Quimioterapia Combinada , Glaucoma/metabolismo , Masculino , Soluções Oftálmicas , Coelhos , Sulfonamidas/administração & dosagem , Espectrometria de Massas em Tandem , Tiazinas/administração & dosagem , Corpo Vítreo/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA